 A RCT of vitamin D supplementation (12000 IU, 24000 IU and 48000 IU) given monthly for one year in people aged 70+ years was conducted to test the effect on Grip Strength (GS) and Timed-up and Go test (TUG).  Older adults with plasma 25hydroxyvitamin D <25 nmol/L at baseline, had lower GS.  However, no effect of vitamin D supplementation on GS and TUG was seen in any of the treatment groups in older adults.  In the absence of a placebo group, we have not excluded benefit from all three doses.
11.6 (SD 2.9) and 11.9 (SD 3.6) s for the 12000 IU, 24000 IU and 48000 IU dose groups, respectively. Baseline plasma 25OHD concentration < 25 nmol/L was associated with lower GS (P=0.003). Post-interventional plasma 25OHD concentrations increased to 55.9 (SD 15.6), 64.6 (SD15.3) and 79.0 (SD 15.1) nmol/L in the 12000 IU, 24000 IU and 48000 IU dose groups, respectively and there was a significant dose-related response in post-interventional plasma 25OHD concentration (p<0.0001). Post-interventional GS values were 24.1 (SD 10.1), 26 .2 (SD10.6) and 25.7 (SD 9.4) kg and TUG test values were 11.5 (SD 2.6), 12.0 (SD 3.7) and 11.9 (SD 3.2) s for 12000 IU, 24000 IU and 48000 IU dose groups, respectively. The change (Δ) in GS and TUG from pre to post-intervention was not different between treatment groups before and after the adjustment for confounders, suggesting no effect of the intervention. Plasma 25OHD concentration was not associated with GS and TUG test after supplementation. In conclusion, plasma 25OHD concentration < 25 nmol/L was associated with lower GS at baseline. However, monthly vitamin D3 supplementation with 12000 IU, A C C E P T E D M A N U S C R I P T
Introduction
Loss of muscle mass and decreased muscle strength are features of ageing, with an annual loss of muscle mass of 0.5 -1.0 % per year after 70 years of age [1] and a 10 -15% decline in muscle strength per decade in older people aged 70-79 years [2] . Decreased muscle mass and strength can result in sarcopenia, which is associated with poorer quality of life, loss of independence and increased health care costs [3] . Assessment of Hand Grip Strength (GS) and Timed-Up and Go (TUG) are the widely used methods to test the muscle strength and identify the presence of sarcopenia [4] .
Links between vitamin D status and muscle function have been reported based on mechanistic in vitro studies [5] , human observational [6, 7, 8, 9, 10, 11] , longitudinal [12] and intervention studies [13, 14] . Some observational [6, 9, 13] and longitudinal [12] studies have reported positive associations between serum 25-hydroxyvitamin D (25OHD) concentration and muscle function in older adults, whereas other studies did not find an association [11] . These conflicting findings may be due to the differences in the characteristics of the population and differences in the vitamin D status of the participants. Current evidence suggests that vitamin D status is associated with reduced muscle strength, function and physical performance in older adults (over 60 years of age) only when serum 25OHD concentration falls below 50 nmol/L [15] . The scientific advisory committee on nutrition (SACN) recommended that serum 25OHD concentration should be at least 25 nmol/L all year round for optimal bone and muscle health [16] .
The findings from vitamin D intervention studies are inconsistent, reflecting the variation in characteristics of the study population (e.g. age, gender, baseline vitamin D status), study design and nature of the intervention (route, dose, frequency and form of vitamin D supplementation). Some studies show the positive effect of vitamin D supplementation on muscle function only in older adults whose baseline serum 25OHD concentrations <30 nmol/L [17] or <50 nmol/L [15] .
Since the plasma concentration and vitamin D supply required for optimal muscle function in older adults are not well understood, we undertook a secondary analysis of a 1-year doseranging randomised vitamin D3 supplementation trial, to evaluate its effects on muscle function [18] .
Materials and methods
Vitamin D in older people (VDOP) study was a randomized double-blind interventional trial in 379 male and female older adults aged 70 years or older, living in the North-East of England Germany) on bone mineral density [18] .
Potential participants were identified through screening of the electronic records of 25 GP practices. Exclusion criteria comprised: taking vitamin D supplements at a dose greater than 400 IU/day or calcium at a dose greater than 500 mg/day, a fragility fracture within the previous 
Intervention and study visits
Participants were randomized to receive one of three doses of vitamin D3, 12000 IU, 24000 IU or 48000 IU, monthly for one year. Both participants and investigators were blinded to the treatment received. Study visits took place at baseline and thereafter at 3-monthly intervals (5 in total). Participants were provided with 3-monthly supplies of vitamin D3 at each study visit.
Outcome measures
GS (kg) in both the right and left hand was measured using a Jamar hand-grip dynamometer (Jamar, Bollington, USA). Three measurements were taken, and the mean value was used for analysis. The TUG test was performed once and recorded as the time taken in seconds (s) to stand from a sitting position in an arm chair and walk 3m distance [20] . GS and TUG were measured before and after 1 year of supplementation. Anthropometry, including, height, weight, Fat Mass (FM) and Fat-Free Mass (FFM) were measured at three-month intervals.
Height was measured using a stadiometer and weight, FM and FFM were measured using a bioelectrical impedance analyser (Tanita Crop, Tokyo, Japan 
Data and statistical analysis
Baseline data were available for 379 older adults, while 343 older adults completed the intervention study. Thus, the total sample of 379 was used for the baseline data analysis, while the data from 343 older adults were used to investigate the intervention effects after 12 months.
Older adults were sub-divided into two groups based on baseline plasma 25OHD concentration < 25 nmol/L, which is the cut-off of value of vitamin D used in the UK to indicate an increased risk of deficiency [16] and plasma 25OHD concentration < 50 nmol/L, which is the cut-off for vitamin D inadequacy used in North America [21] , both of which have recently been incorporated in to the National Osteoporosis guidelines in the UK [22] . Statistical analysis of the data was conducted using SPSS for Windows version 13.0. Kolmogorov-Smirnov test was used to evaluate the distribution of the variables and those that were not normally distributed
were log transformed prior to the analysis and were near normally distributed after the conversion. Primary outcomes for the study were GS and TUG in response to supplementation with 12000 IU, 24000 IU and 48000 IU vitamin D3 per month. function after supplementation. A P value <0.05 was considered as significant. Table 1 presents the participants' characteristics at baseline, stratified by vitamin D3 supplementation dose. Baseline values for the main outcome measures, GS, TUG and plasma 25OHD concentration were similar across the intervention groups as were mean values for the main confounders including weight, height, BMI and age indicating that randomization was successful. The initial characteristics of the baseline sample (379 participants) and the sample of older adults who completed the intervention study (343 participants) were similar (data are not shown). IU, 24000 IU and 48000 IU dose group, respectively. There was no significant difference between the groups in unadjusted PTH post-intervention, although the decrease in PTH was significant larger at the highest dose after correction for confounders. In subgroup analyses, change in PTH was significantly different between intervention arms before and after adjusting for confounders comparing those with baseline 25OHD concentrations equal to or above with those below 50 nmol/L at baseline but this was not the case for the 25 nmol/L cut point (Table   3) . 
Results
After supplementation, plasma 25OHD concentration was not significantly associated with either GS or TUG. Significant determinants for GS after supplementation were height (p<0.0001), gender (p=<0.0001), age (p=0.002), concurrent body weight (p=0.040) and FM (p= 0.040). Similarly, the determinants of TUG were age (p<0.0001), height (p < 0.0001), fat mass (p=<0.0001), gender (p=0.018) and vitamin D intake (p=0.019) (data are not shown).
Discussion

Main findings
This double-blind, randomized controlled study found that monthly vitamin D3 supplementation with 12000 IU, 24000 IU and 48000 IU (which corresponds to 400, 600 and 1200 µg of dietary vitamin D per day) for one year produced significant dose-related increases in plasma 25OHD concentration but had no effect on muscle function in older adults. However, at baseline, there was an association between plasma 25OHD concentration and GS, with significantly lower GS for those with baseline plasma 25OHD concentration <25 nmol/L in both males and females. After supplementation, there were no associations between plasma 25OHD concentration and muscle function. To our knowledge, this is the first dose-ranging RCT conducted in the UK, with a large number of free-living older adults, evaluating the effect of vitamin D supplementation on muscle function.
Comparison with other studies
In line with our findings, previous RCTs reported that vitamin D supplementation had no beneficial effect on muscle function in older adults, irrespective of the dose of vitamin D supplements given. A recent study of female adults of long-term care residence aged 65+ years, supplemented with the oral dose of 800 IU vitamin D3 daily for 24 months, reported no effect of the supplementation on muscle function measured by gait speed and physical performance test [23] . Another study that conducted recruiting home-dwelling men and women aged > 70 years who were randomized to receive one of the oral doses of 24000 IU, 60000 IU or 24000 IU vitamin D3 with 300 µg of calcifediol monthly for 12 months, reported no improvement in lower extremity function measured by short physical performance battery [24] . Hansen et al., 2015 reported that among postmenopausal women aged 75 years or younger with baseline 25OHD concentration 14 -27 ng/mL, (~ 35 -67.5 nmol/L) and supplemented with an oral dose of 800 IU or 50000 IU vitamin D3 twice monthly for one year had no effect on muscle function, assessed by the 'five sit-stand' test and TUG test [25] . Further, a recent systematic review of community-dwelling older adults aged 65+ years showed that bolus injection or oral
vitamin D supplementation of dose ranging from 1000 IU -600,000 IU, given daily or weekly for duration ranging from 16 weeks to 20 months, had no effect on GS and TUG test [26] .
In Similar to our study Grimaldi et al., 2013 , also reported a positive association between serum 25OHD concentration and GS, but not with other tests of muscle function and suggested that this might be related to anatomical site differences in the androgenic effect of vitamin D or to differences in vitamin D receptor expression between upper and lower body muscle and consequently muscle function [34] .
GS loss in our study was much higher than the reported values in previous studies. The annual loss of GS among the older people aged 65 -75 years reported in previous studies ranged from 0.3 to 1.3 kg [35, 36, 37] . Though the GS is the standard method to assess sarcopenia, differences in the equipment and methods used in various studies may have caused variation in the measurements, making it difficult to compare between studies [38] .
In this study we found that plasma 25OHD concentration < 25 nmol/L was associated with a lower GS. This finding supports the recommendation of SACN, UK that for the protection of Accordingly, it can be speculated that the dosages used in this study may not have been high enough to reduce the negative effects of the ageing process. The absence of a detectable effect of supplementation in this study may also be attributed to the fact that only 30% of our participants had a 25OHD <25 nmol/l at baseline. However, as a result of lack of a placebo group we did not have data on "natural decline" of muscle function of this group, thus we could not compare the effect of vitamin D supplementation with that in non-supplemented individuals.
For tissues other than the kidney, total 25OHD may not fully reflect its availability for local hydroxylation into 1,25(OH)2D, which is the active metabolite of vitamin D. Although 1,25(OH)2D is responsible for the biological action of vitamin D, its systemic concentration does not reflect function at the target tissue level [43, 44] . Many vitamin D target tissues,
including the muscle tissue, are known to express the 1,25(OH)2D-producing enzyme CYP27A1 for auto-and paracrine functions. Some reports suggest that muscle tissue may be capable of internalising vitamin D binding protein bound 25OHD, although it remains to be determined whether this is a significant route of cellular supply of 25OHD [8] . To date, no data are available to identify whether free 25OHD provides a better prediction of muscle function compared to total 25OHD.
Limitations, strengths and future studies
We used the lowest intervention dose (which corresponds to the current UK dietary recommendation) as the reference group but did not include a placebo group in our study design as directed by the approving authorities. As a result, we could not establish the effect of three This study had several strengths. Its large sample size and the number of available measurements that could potentially influence muscle force, i.e. those related to body composition and size. The use of three different vitamin D doses corresponding to the UK Recommended Nutrient Intake (RNI) [16] , the US Recommended Dietary Allowances (RDA) [21] and the value below the Tolerable Upper Intake Level (TUIL) was a strength of this study.
We considered the effect of vitamin D supplementation, without an exercise intervention, on muscle. Few trials have looked at the potential interaction between exercise and vitamin D, although a recent systematic review presented evidence of an additive effect of resistance exercise and vitamin D3 supplementation for the improvement of muscle strength in older adults, and we would support suggestions that this is an important area for future research [45] .
A C C E P T E D M A N U S C R I P T
Conclusions
At baseline, plasma 25OHD was associated with GS in both male and females, but only below the cut-off level of 25 nmol/L. Vitamin D supplementation significantly increased the plasma 25OHD concentration of older adults in all doses of supplementation. Vitamin D supplementation with 12000 IU, 24000 IU and 48000 IU for 12 months had no effect on muscle function in adults older than 70 years.
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